BIOGEN FDA Friday, September 17, 2021 -0.40 Negative

FDA Approves BYOOVIZ — BIOGEN INC.

Biogen received U.S. regulatory approval on September 17, 2021, to market a biosimilar version of the blockbuster wet AMD treatment ranibizumab. This approval strengthens the biopharmaceutical company’s pipeline and places it in a pivotal position to compete for market share against the original anti-VEGF drug.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed